[Skin lesions related to a new anti-inflammatory agent: fenbufen. Apropos of 3 clinical cases].
Three cases of generalized skin reactions occurred in patients undergoing oral therapy with Fenbufen (Cinopal), a new anti-inflammatory agent. The lesions spontaneously improved when the drug was discontinued. The role of Fenbufen in the pathogenesis of the lesions remains unclear. In the three cases, the detection of circulating immune complexes would suggest a sensibilization mechanism.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000936:Antigen-Antibody Complex / Q000032:analysis; D003875:Drug Eruptions / Q000209:etiology* / Q000276:immunology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010654:Phenylbutyrates; D011422:Propionates / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000936:Antigen-Antibody Complex; D010654:Phenylbutyrates; D011422:Propionates; C010725:fenbufen
Accidents cutanés liés à un nouvel anti-inflammatoire: fenbufène. A propos de 3 cas.